/ -- AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) did not meet the primary endpoint of overall survival (OS) with a hazard ratio (HR) of 0.908; stratified log-rank, p=0.3772.

/ -- 艾伯维（AbbVie，纽约证券交易所代码：ABBV）宣布，全球三期VERONA试验评估维奈托克与阿扎胞苷联合用于治疗新诊断的高危骨髓增生异常综合征（HR-MDS）时，未达到总生存期（OS）的主要终点，风险比（HR）为0.908；分层log-rank检验，p=0.3772。

No new safety signals were observed..

未观察到新的安全信号。

Results from the VERONA trial will be available in a future medical congress and/or publication. Any patients who received venetoclax in combination with azacitidine through participation in the MDS clinical trials will be informed by their treating physician.

VERONA 试验的结果将在未来的医学大会和/或出版物中公布。任何通过参与 MDS 临床试验接受维奈托克联合阿扎胞苷治疗的患者都将由其主治医生告知。

These data do not impact any current approved indications for venetoclax.

这些数据不会影响维奈托克任何当前已批准的适应症。

About

关于

the Phase 3 VERONA Trial

第3阶段VERONA试验

VERONA is a global Phase 3 randomized, controlled trial comparing the efficacy and safety of venetoclax in combination with azacitidine compared to azacitidine and placebo, in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (higher-risk MDS). The primary outcome measure is overall survival (OS).

VERONA 是一项全球性的 III 期随机对照试验，比较了维奈托克联合阿扎胞苷与阿扎胞苷联合安慰剂在治疗新诊断的高危骨髓增生异常综合征（高危 MDS）中的疗效和安全性。主要结局指标是总生存期 (OS)。

Key secondary outcome measures include modified overall response (mOR) and complete remission (CR)..

关键的次要结局指标包括修正的整体反应（mOR）和完全缓解（CR）。

About VENCLEXTA

关于维奈克拉

VENCLEXTA/VENCLYXTO (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis. VENCLEXTA/VENCLYXTO targets the BCL-2 protein and works to help restore the process of apoptosis..

VENCLEXTA/VENCLYXTO（维奈托克）是一种首创的药物，可选择性结合并抑制B细胞淋巴瘤-2（BCL-2）蛋白。在某些血液癌症中，BCL-2蛋白阻止癌细胞经历其自然死亡或自我毁灭的过程，即细胞凋亡。VENCLEXTA/VENCLYXTO靶向BCL-2蛋白，并帮助恢复细胞凋亡的过程。

VENCLEXTA/VENCLYXTO is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. Together, the companies are committed to BCL-2 research and to studying venetoclax in clinical trials across several blood and other cancers.

VENCLEXTA/VENCLYXTO由艾伯维和罗氏共同开发。在美国，该药物由艾伯维与罗氏集团成员基因泰克共同商业化，而在美国以外则由艾伯维负责。两家公司共同致力于BCL-2研究，并在多种血液癌症及其他癌症的临床试验中对维奈托克进行研究。

Venetoclax is approved in more than 80 countries, including the U.S..

维奈托克已在包括美国在内的 80 多个国家获得批准。

About AbbVie

关于艾伯维

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio.

艾伯维的使命是发现并提供创新的药物和解决方案，以解决当今严重的健康问题，并应对未来的医学挑战。我们力求在免疫学、肿瘤学、神经科学和眼科护理等几个关键治疗领域以及我们艾尔建美学产品组合中的产品和服务方面，对人们的生活产生显著影响。

About AbbVie in Oncology

关于AbbVie在肿瘤学领域

At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination.

在艾伯维，我们致力于改变难治性癌症患者的标准治疗。我们正在推进一系列癌症类型的血液癌和实体瘤的动态研究疗法管线。我们专注于创造靶向药物，这些药物要么阻碍癌细胞的繁殖，要么促使它们的清除。

We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and in situ CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines..

我们通过各种有针对性的治疗方式和生物干预来实现这一目标，包括小分子治疗药物、抗体-药物偶联物 (ADC)、基于免疫肿瘤学的治疗药物、多特异性抗体和原位CAR-T平台。我们敬业且经验丰富的团队与创新合作伙伴携手，加速潜在突破性药物的交付。

Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines.

今天，我们广泛的肿瘤学产品组合包括已批准和正在研究的针对多种血液和实体肿瘤的治疗方法。我们正在针对一些全球最普遍和最具衰弱性的癌症进行多项临床试验，评估超过 20 种在研药物。在努力对人们的生活产生显著影响的同时，我们致力于探索解决方案，帮助患者获得我们的抗癌药物。